Asgpr-binding compounds for the degradation of extracellular proteins
US-2024424108-A1 · Dec 26, 2024 · US
Apelin polypeptides
US11807693B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11807693-B2 |
| Application number | US-202117160819-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 28, 2021 |
| Priority date | Jun 10, 2014 |
| Publication date | Nov 7, 2023 |
| Grant date | Nov 7, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
First claim
Opening claim text (preview).
What is claimed: 1. A method for treating heart failure in a subject in need thereof comprising administering to the subject an isolated polypeptide comprising the amino acid sequence SEQ ID NO: 16; and wherein the polypeptide is conjugated to polyethelyene glycol by 3-mercaptopropanoic acid. 2. The method of claim 1 , wherein dP/dt max , and/or ejection fraction is increased in the subject following administration of the polypeptide. 3. The method of claim 1 , wherein systolic or diastolic function is improved in the subject following administration of the polypeptide. 4. The method of claim 1 , wherein the heart failure is heart failure with reduced ejection fraction. 5. A method of improving cardiac contractility in a subject having a cardiovascular condition comprising administering to the subject the polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence SEQ ID NO: 16; and wherein the polypeptide is conjugated to polyethylene glycol by 3-mercaptopropanoic acid; and wherein cardiac contractility is improved in the subject following administration. 6. A method of increasing ejection fraction in a subject having a cardiovascular condition comprising administering to the subject the polypeptide of claim 1 , wherein the polypeptide SEQ ID NO: 16, and wherein the polypeptide is conjugated to polyethelyene glycol by 3-mercaptopropanoic acid and wherein the ejection fraction is increased following administration of the polypeptide.
Assignees
Inventors
Classifications
- C07K7/08Primary
having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title
Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title
Carboxylic acids, e.g. a fatty acid or an amino acid · CPC title
the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title
- C07K14/47Primary
from mammals · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11807693B2 cover?
- The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
- Who is the assignee on this patent?
- Amgen Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K7/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).